CDER Director Adam Sherwat Exits FDA During Turbulent Period
Dr. Adam Sherwat, who has served as acting director of the FDA Center for Drug Evaluation and Research (CDER), has left the agency effective this week, according to an internal memo obtained by multiple news outlets. His departure comes amid a particularly contentious period for the division responsible for evaluating and approving new drugs in the United States.
CDER is the largest of the FDA centers, overseeing the approval and regulation of prescription and over-the-counter drugs, biological therapeutics, and generic medications. The center has been at the center of several controversies in recent months related to approval standards, staffing shortages, and questions about political influence on regulatory decisions.
Background on the Departure
Sherwat, an infectious disease physician who joined the FDA in 2017, had been serving in the acting director role since late 2025. He previously held leadership positions in CDER Office of New Drugs and was widely regarded as a technically skilled regulator with deep institutional knowledge.
According to sources familiar with the situation, Sherwat departure was driven by a combination of factors including disagreements with senior agency leadership over the pace and standards of drug approvals, frustration with ongoing staffing challenges that have left critical review divisions understaffed, and personal considerations.
"Dr. Sherwat is a dedicated public servant who cared deeply about getting drug regulation right. His departure is a loss for the agency and for public health," said a former FDA official who worked closely with him, speaking on condition of anonymity.
Controversies Surrounding CDER
The center has faced scrutiny from multiple directions in recent months. Congressional Republicans have pressed the FDA to accelerate drug approvals, arguing that overly cautious review timelines are delaying patient access to needed treatments. Meanwhile, some scientists and consumer advocacy groups have expressed concern that political pressure could lead to approvals based on insufficient evidence.
Several specific decisions have drawn particular attention:
- The accelerated approval of a controversial Alzheimer therapy despite mixed clinical data
- Questions about the adequacy of post-market safety monitoring for recently approved weight loss medications
- Delays in approving generic versions of several high-cost brand-name drugs
- Staffing vacancies that have slowed review timelines across multiple therapeutic areas
Impact on Drug Review Pipeline
The leadership vacancy at CDER comes at a particularly busy time for the center. Several major drug approvals are pending in the coming months, including new treatments for rare diseases, mental health conditions, and oncology indications. Industry observers have expressed concern that the transition could create additional delays in an already strained review system.
The FDA said in a statement that a successor for the acting director role would be announced shortly and that drug review operations would continue without interruption. The agency declined to provide further details about the circumstances of Sherwat departure.
Broader FDA Challenges
Sherwat exit is the latest in a series of high-profile departures from the FDA that have raised questions about leadership stability and morale at the agency. The FDA has lost several senior officials over the past year, including experienced reviewers and division directors whose institutional knowledge is difficult to replace.
The situation has drawn concern from former FDA commissioners of both parties. "Stable, experienced leadership at CDER is essential for maintaining the integrity of the drug approval process. Frequent turnover in senior positions undermines institutional continuity and can affect the quality and consistency of regulatory decisions," one former commissioner said.
For the pharmaceutical industry, patient advocacy groups, and the broader healthcare system, the question of who will lead CDER and what direction the center will take on approval standards remains one of the most consequential regulatory questions of 2026.
